Sharescart Research Club logo ×
Screener Research Unlisted Startup Funding New IPO New

Nath Bio-Genes

₹190.9 -2.8 | 1.4%

Market Cap ₹363 Cr.

Stock P/E 8.7

P/B 0.6

Current Price ₹190.9

Book Value ₹ 320.9

Face Value 10

52W High ₹243.7

Dividend Yield 1.05%

52W Low ₹ 159.4

Nath Bio-Genes Research see more...

Overview Inc. Year: 2000Industry: Agriculture

Nath Bio-Genes (India) Ltd engages inside the production, processing, and advertising of hybrid and GM seeds in India and the world over. It operates in segments, Agricultural Activities and Trading Activities. The company gives seeds for cereals, which include maize, paddy, millet, wheat, and jowar; fruit seeds; fiber and oil seeds, consisting of cotton and mustard; and seeds for vegetables comprising chilli, okra, tomato, brinjal, bottle gourd, bitter gourd, sponge gourd, ridge gourd, cucumber, coriander, onion, sweet peeper, green peas, pumpkin, tinda, cabbage, and French beans. It also gives crop protection supplements, along with WINPro GOLii, WINall, and Win Chi Win boom enhancer; and forage supplements, consisting of NUTRIMAX GOLD and NUTRIMAX for enhanced fodder yields. The organisation offers its merchandise through a network of distributors, sellers, and processing plants. Nath Bio-Genes (India) Ltd became founded in 1979 and is primarily based in Aurangabad, India.

Read More..

Nath Bio-Genes Share Price

New

| |

Volume
Price

Quarterly Price

Show Value Show %

Peer Comparison

Nath Bio-Genes Quarterly Results

#(Fig in Cr.) Mar 2022 Jun 2022 Sep 2022 Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024
Net Sales 27 209 22 25 45 235 23 32 43
Other Income 1 0 0 0 0 0 0 0 0
Total Income 28 209 22 25 45 235 23 32 43
Total Expenditure 49 175 17 20 41 198 17 26 39
Operating Profit -21 34 5 6 4 37 6 6 4
Interest 2 3 3 3 2 3 2 3 1
Depreciation 1 1 1 1 1 1 1 1 1
Exceptional Income / Expenses -89 0 0 0 0 0 0 3 0
Profit Before Tax -113 31 2 2 2 33 2 5 2
Provision for Tax 3 0 0 1 0 0 0 1 1
Profit After Tax -116 31 1 1 1 33 2 4 2
Adjustments -0 0 0 0 -0 0 -0 0 1
Profit After Adjustments -116 31 1 1 1 33 2 4 3
Adjusted Earnings Per Share -61.2 16.2 0.8 0.7 0.8 17.5 1.1 2 1.4

Nath Bio-Genes Profit & Loss

#(Fig in Cr.) Mar 2012 Mar 2013 Mar 2022 Mar 2023 TTM
Net Sales 124 138 278 301 333
Other Income 1 1 2 1 0
Total Income 125 138 280 302 333
Total Expenditure 109 118 241 253 280
Operating Profit 16 20 39 49 53
Interest 2 4 11 10 9
Depreciation 5 5 3 3 4
Exceptional Income / Expenses 0 0 -89 0 3
Profit Before Tax 9 12 -63 36 42
Provision for Tax -0 1 4 1 2
Profit After Tax 9 12 -67 35 41
Adjustments 0 0 0 0 1
Profit After Adjustments 9 12 -67 35 42
Adjusted Earnings Per Share 0 0 -35.5 18.4 22

Growth Rates

# 1 Year 3 Year 5 Year 10 Year
Sales CAGR 8% 34% 0% 0%
Operating Profit CAGR 26% 45% 0% 0%
PAT CAGR 0% 57% 0% 0%
# 1 Year 3 Year 5 Year 10 Year
Share Price CAGR 13% -18% -15% 10%
ROE Average 6% 2% 7% 7%
ROCE Average 7% 5% 9% 9%

Nath Bio-Genes Balance Sheet

#(Fig in Cr.) Mar 2012 Mar 2013 Mar 2022 Mar 2023
Shareholder's Funds 46 57 542 573
Minority's Interest 0 0 -0 -0
Borrowings 1 1 1 0
Other Non-Current Liabilities 1 1 3 3
Total Current Liabilities 72 98 194 216
Total Liabilities 119 157 739 793
Fixed Assets 21 38 245 244
Other Non-Current Assets 2 0 27 28
Total Current Assets 96 120 468 521
Total Assets 119 157 739 793

Nath Bio-Genes Cash Flow

#(Fig in Cr.) Mar 2012 Mar 2013 Mar 2022 Mar 2023
Opening Cash & Cash Equivalents 0 3 29 4
Cash Flow from Operating Activities 0 14 17 38
Cash Flow from Investing Activities 0 -21 -20 -3
Cash Flow from Financing Activities 0 6 -22 -2
Net Cash Inflow / Outflow 0 -1 -25 34
Closing Cash & Cash Equivalent 0 2 4 38

Nath Bio-Genes Ratios

# Mar 2012 Mar 2013 Mar 2022 Mar 2023
Earnings Per Share (Rs) 0 0 -35.46 18.43
CEPS(Rs) 8.69 10.16 -33.84 20.01
DPS(Rs) 0 0 2 2
Book NAV/Share(Rs) 0 0 285.16 301.61
Core EBITDA Margin(%) 11.84 14.45 13.37 16.21
EBIT Margin(%) 8.78 11.6 -18.96 15.39
Pre Tax Margin(%) 7.32 8.93 -22.79 12
PAT Margin (%) 7.42 8.53 -24.21 11.62
Cash Profit Margin (%) 11.22 11.8 -23.1 12.62
ROA(%) 7.73 8.5 -15.03 4.57
ROE(%) 20.12 22.76 -22.48 6.28
ROCE(%) 19.09 23.88 -14.84 7.06
Receivable days 36.68 44.32 69.85 110.74
Inventory Days 193.69 189.43 195.06 259.3
Payable days 1576.65 -4219.16 1503.38 744.29
PER(x) 0 0 0 7.69
Price/Book(x) 0 0 0.75 0.47
Dividend Yield(%) 0 0 0.94 1.41
EV/Net Sales(x) 0.19 0.24 1.78 1.12
EV/Core EBITDA(x) 1.54 1.6 12.65 6.81
Net Sales Growth(%) 0 11.13 102.15 8.26
EBIT Growth(%) 0 46.76 -430.58 187.85
PAT Growth(%) 0 27.66 -673.7 151.96
EPS Growth(%) 0 0 -583.1 151.98
Debt/Equity(x) 0.25 0.33 0.17 0.18
Current Ratio(x) 1.34 1.22 2.41 2.41
Quick Ratio(x) 0.42 0.43 1.27 1.45
Interest Cover(x) 6.02 4.35 -4.96 4.54
Total Debt/Mcap(x) 0 0 0.23 0.39

Nath Bio-Genes Shareholding Pattern

# Dec 2021 Mar 2022 Jun 2022 Sep 2022 Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024
Promoter 41.03 41.05 41.07 45.6 45.6 45.6 45.6 45.6 45.6 45.6
FII 0.04 0.07 0.11 0.01 0.15 0.13 0.07 0.22 0.32 0.27
DII 7.16 4.85 4.62 4.62 4.62 4.62 4.62 4.37 4.37 4.37
Public 51.76 54.02 54.2 49.77 49.63 49.65 49.71 49.81 49.72 49.76
Others 0 0 0 0 0 0 0 0 0 0
Total 100 100 100 100 100 100 100 100 100 100

Pros

  • Stock is trading at 0.6 times its book value
  • Debtor days have improved from 1503.38 to 744.29days.
  • Company has reduced debt.
  • Company is almost debt free.

Cons

  • Promoter holding is low: 45.6%.
  • Company has a low return on equity of 2% over the last 3 years.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Nath Bio-Genes News

Top Unlisted Companies & InstaBuy Companies

Sell or Purchase Share (Tentative Price)

IPO

Companies Open Date Close Date Issue Price Cost of 1 Lot GMP Expected Listing Listing Gain(%) Listing Price Current Price Type Exchange

View more.....

Companies Open Date Close Date Issue Price Cost of 1 Lot GMP Expected Listing Listing Gain(%) Listing Price Current Price Type Exchange

View more.....

Companies Open Date Close Date Issue Price Cost of 1 Lot GMP Expected Listing Listing Gain(%) Listing Price Current Price Type Exchange

View more.....

Companies Open Date Close Date Issue Price Cost of 1 Lot GMP Expected Listing Listing Gain(%) Listing Price Current Price Type Exchange

View more.....

Companies Open Date Close Date Issue Price Cost of 1 Lot GMP Expected Listing Listing Gain(%) Listing Price Current Price Type Exchange

View more.....